---
schema_version: "secwatch.filing_event.v1"
accession: "0000078003-24-000103"
form_type: "8-K"
ticker: "PFE"
cik: "0000078003"
company_name: "PFIZER INC"
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T03:32:17.025772+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pfizer Q1 revenue $14.9B (-20% YoY); adj. EPS $0.82; raises FY adj. EPS guidance

## Summary
- Q1 revenue $14.9B, operational decline 19% YoY; ex-COVID products grew 11% operationally.
- Reported diluted EPS $0.55; adjusted diluted EPS $0.82 (includes $0.11 favorable Paxlovid return adjustment).
- Full-year 2024 revenue guidance reaffirmed at $58.5-$61.5B; adjusted EPS guidance raised to $2.15-$2.35.
- Cost realignment program on track to deliver at least $4 billion net cost savings by end of 2024.
- Notable approvals: Beqvez (hemophilia B) FDA approval, Prevenar 20 (pediatrics) EU approval, Tivdak full FDA approval.

## SEC filing metadata
- accession: 0000078003-24-000103
- form_type: 8-K
- ticker: PFE
- cik: 0000078003
- company_name: PFIZER INC
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/78003/000007800324000103/0000078003-24-000103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/78003/000007800324000103/pfe-20240501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000078003-24-000103
- JSON: https://secwatch.observer/filing/0000078003-24-000103.json
- Plain text: https://secwatch.observer/filing/0000078003-24-000103.txt

## Key facts
- Earnings Releases
  PFIZER INC reported first quarter of 2024 results: revenue $14,879 million, net income $3,115 million, EPS $0.55. Guidance raised.
  - Period: first quarter of 2024
  - Revenue: $14,879 million
  - Net income: $3,115 million
  - EPS: $0.55
  - Guidance: raised
  - Result: reported results
  source text: First-Quarter 2024 Results ▪ Solid First-Quarter Results Reflect Continued Growth of Key Products and Progress in Executing 2024 Priorities ▪ First-Quarter 2024 Revenues of $14.9 Billion – Expected Decline in Comirnaty (1) and Paxlovid Revenues Drove a Year-Over-Year Operational Decrease in Revenues of 19% – Excluding Contributions from Comirnaty (1) and
  evidence_url: https://www.sec.gov/Archives/edgar/data/78003/000007800324000103/0000078003-24-000103-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.